Standout Papers

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe al... 2001 2026 2009 2017 956
  1. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma (2001)
    William W. Busse, Jonathan Corren et al. Journal of Allergy and Clinical Immunology
  2. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial (2016)
    J. Mark FitzGerald, Eugene R. Bleecker et al. The Lancet
  3. Exploring the Effects of Omalizumab in Allergic Asthma (2013)
    Nicola A. Hanania, Sally E. Wenzel et al. American Journal of Respiratory and Critical Care Medicine
  4. Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children (2011)
    William W. Busse, Wayne J. Morgan et al. New England Journal of Medicine
  5. Role of viral respiratory infections in asthma and asthma exacerbations (2010)
    William W. Busse, Robert F. Lemanske et al. The Lancet
  6. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma (2007)
    Patrick Flood-Page, Cheri A. Swenson et al. American Journal of Respiratory and Critical Care Medicine
  7. Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma (2013)
    William W. Busse, Stephen T. Holgate et al. American Journal of Respiratory and Critical Care Medicine
  8. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis (2013)
    Wendy C. Moore, Annette T. Hastie et al. Journal of Allergy and Clinical Immunology
  9. Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy (2011)
    Nicola A. Hanania, Oral Alpan et al. Annals of Internal Medicine
  10. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations (2015)
    Stephen J. Teach, Michelle A. Gill et al. Journal of Allergy and Clinical Immunology
  11. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia (2013)
    Michel Laviolette, David Gossage et al. Journal of Allergy and Clinical Immunology
  12. Type 2 immunity in the skin and lungs (2020)
    Cezmi A. Akdiş, Peter D. Arkwright et al. Allergy
  13. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study (2014)
    Mario Castro, Sally E. Wenzel et al. The Lancet Respiratory Medicine
  14. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment (2017)
    Stephen P. Peters, William W. Busse et al. The Journal of Allergy and Clinical Immunology In Practice

Immediate Impact

6 by Nobel laureates 8 from Science/Nature 140 standout
Sub-graph 1 of 14

Citing Papers

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
2024 Standout
Asthma
2023 Standout
192 intermediate papers

Works of William W. Busse being referenced

Holy Grail: the journey towards disease modification in asthma
2022
Exploring the Effects of Omalizumab in Allergic Asthma
2013 Standout
and 168 more

Author Peers

Author Last Decade Papers Cites
William W. Busse 25643 16406 8256 520 33.6k
Sally E. Wenzel 26889 18317 6208 328 33.8k
Paul M. O’Byrne 29721 22141 7468 510 37.1k
Qutayba Hamid 22365 10000 9856 496 36.9k
Andrew J. Wardlaw 19199 12320 5649 252 26.6k
Christopher E. Brightling 20456 16720 3498 405 28.0k
Ian Pavord 27308 23603 4160 501 33.7k
Pascal Chanez 18206 14143 4434 408 24.8k
Peter G. Gibson 28429 21363 3163 958 51.3k
Per Venge 11077 7120 4805 560 31.2k
Fernando D. Martínez 20209 15514 5294 257 30.5k

All Works

Loading papers...

Rankless by CCL
2026